hide message

Hello! Welcome to the Resource Centre.

We hope you find our free tools and resources useful. Did you know we also work directly with community advocates, providing them with the skills and resources to document corporate human rights abuses and effectively communicate with business?

This is only possible through generous donations from people like you.

Please consider supporting our work.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Oxfam report "Investing for Life": Company responses & Oxfam rejoinder

In November 2007, Oxfam issued a report, "Investing for life: Meeting  poor people's needs for access to medicines through responsible business practices".  In the report, Oxfam examines the business conduct of 12 pharmaceutical companies with respect to access to medicines for the poor.  The Business & Human Rights Resource Centre invited all 12 companies to respond to the report.  The results to date are below (any future responses received will be added to this page).

On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses: "Oxfam rejoinder" [DOC]

Company responses / non-responses:

Abbott Laboratories statement [DOC]

AstraZeneca statement [DOC]

Bristol-Myers Squibb did not respond

GlaxoSmithKline statement [DOC]

Eli Lilly declined to respond

Johnson & Johnson statement [DOC]

Merck statement [PDF]

Novartis statement [DOC]

Pfizer statement [DOC]
- Pfizer's Malaria Platform [DOC]

Roche declined to respond

Sanofi-Aventis statement [PDF] 

Wyeth did not respond

 

Oxfam Gets A Cold Shoulder From Drugmakers, Pharmalot, 5 Feb 2008 (article commenting on Oxfam's report, the companies' responses, and Oxfam's rejoinder)

- Drug makers reject Oxfam targets, in Ethical Corporation, Mar 2008 (scroll down to middle of article)

Get RSS feed of these results

Related stories and components

Company response
12 February 2008

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read full response

Company non-response
19 December 2007

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read more

Company response
18 December 2007

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read full response

Company response
18 December 2007

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read full response

Company non-response
12 December 2007

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read more

Company non-response
12 December 2007

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read more

Article
12 December 2007

Oxfam report "Investing for Life": Company responses

Author: Compiled by the Business & Human Rights Resource Centre

The Business & Human Rights Resource Centre invited all 12 [pharmaceutical] companies to respond to the report. The results to date are below (any future responses received will be added to this page)...On 6 February 2008 Oxfam sent a rejoinder,...

Read more

Company response
12 December 2007

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read full response

Company response
12 December 2007

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Read full response

Company response
12 December 2007

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Read full response